{
    "name": "radium-223 dichloride",
    "comment": "Rx",
    "other_names": [
        "Xofigo"
    ],
    "classes": [
        "Radiopharmaceuticals"
    ],
    "source": "https://reference.medscape.com/drug/xofigo-radium-223-dichloride-999852",
    "pregnancy": {
        "common": [
            "Safety and efficacy have not been established in females; based on mechanism of action, drug can cause fetal harm when administered to a pregnant female; while there are no human or animal data on use in pregnancy, maternal use of a radioactive therapeutic agent could affect development of a fetus; Advise pregnant females and females of reproductive potential of the potential risk to a fetus"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Safety and efficacy not established in females; there is no data on presence of radium-223 dichloride in human milk, effects on breastfed child, or on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy; radium-223 can cause fetal harm when administered to a pregnant woman based on its mechanism of action; not indicated for use in women and is contraindicated in women who are or may become pregnant"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause myelosuppression and bone marrow failure; perform hematologic evaluation at baseline and prior to every dose; discontinue if life-threatening complications occur despite supportive care for bone marrow failure",
                "Safety and efficacy of concomitant chemotherapy have not been established; outside of a clinical trial, concomitant use with chemotherapy is not recommended due to the potential for additive myelosuppression",
                "Not recommended for use in combination with abiraterone acetate plus prednisone/prednisolone outside of clinical trials; increased fractures and mortality reported",
                "Because of potential effects on spermatogenesis associated with radiation, advise men who are sexually active to use condoms and their female partners of reproductive potential to use a highly effective contraceptive method during and for 6 months after completing treatment"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Percentages includes all toxicity grades",
            "percent": "1-4"
        },
        {
            "name": "Anemia",
            "percent": "93"
        },
        {
            "name": "Lymphocytopenia",
            "percent": "72"
        },
        {
            "name": "Leukopenia",
            "percent": "35"
        },
        {
            "name": "Thrombocytopenia",
            "percent": "31"
        },
        {
            "name": "Nausea",
            "percent": "36"
        },
        {
            "name": "Diarrhea",
            "percent": "25"
        },
        {
            "name": "Vomiting",
            "percent": "19"
        },
        {
            "name": "Neutropenia",
            "percent": "18"
        },
        {
            "name": "Peripheral edema",
            "percent": "13"
        },
        {
            "name": "Percentages includes all toxicity grades",
            "percent": "1-4"
        },
        {
            "name": "Renal failure and impairment",
            "percent": "3"
        },
        {
            "name": "Dehydration",
            "percent": "3"
        },
        {
            "name": "Pancytopenia",
            "percent": "2"
        },
        {
            "name": "Erythema",
            "percent": "1"
        },
        {
            "name": "pain",
            "percent": null
        },
        {
            "name": "and edema at injection site",
            "percent": null
        }
    ]
}